(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

What is it about?

Apparent treatment-resistant hypertension (aTRH) appears common in clinical practice. However, this paper demonstrates that most cases of aTRH may be due to "pseudo-resistance" (i.e., inadequate dosing of anti-hypertensive drugs, white-coat hypertension, and/or poor adherence).

Why is it important?

Patients with aTRH who are pseudo-resistant are at risk of increased morbidity and unnecessary intensification of treatment. Consideration of dosing, white-coat effects, and adherence may be all that is required for hypertension management in the majority of cases.

Read more on Kudos…
The following have contributed to this page:
Hannah Durand
' ,"url"));